Enhanced bacteremia in human factor H transgenic rats infected by neisseria meningitidis

Infection and Immunity

Volumn 80, Issue 2, 2012, Pages 643-650

  Vu, David M ^a   Shaughnessy, Jutamas ^b   Lewis, Lisa A ^b   Ram, Sanjay ^b   Rice, Peter A ^b   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; LIGAND; LIPOOLIGOSACCHARIDE; SIALYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BLOOD CULTURE; COLONY FORMING UNIT; EMBRYO; ENCAPSULATION; INNATE IMMUNITY; LIGAND BINDING; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SERUM; TRANSGENE; WILD TYPE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, BACTERIAL; BACTEREMIA; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; COMPLEMENT FACTOR H; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; RATS;

EID: 84857144559     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05604-11     Document Type: Article

References (38)

1. Agarwal S, et al. 2010. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J. Immunol. 185:507-516.
2. Agarwal S, et al. 2011. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. mBio 2(5):e00178 -111. doi:10.01128/mBio.00178 -111.
3. Beernink PT, et al. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186:3606 -3614.
4. Borrow R, et al. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12:970 -976.
5. Brodeur BR, et al. 1985. Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotypespecific monoclonal antibody. Infect. Immun. 50:510 -516.
6. Demares MJ, Davrinche C. 1990. Prevalence of the 1.8-kb complement factor H mRNA in human lung. Immunology 70:150 -154.
7. Dunphy KY, Beernink PT, Brogioni B, Granoff DM. 2011. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect. Immun. 79:353-359.
8. Edwards JL, Apicella MA. 2002. The role of lipooligosaccharide in Neisseria gonorrhoeae pathogenesis of cervical epithelia: lipid A serves as a C3 acceptor molecule. Cell Microbiol. 4:585-598.
9. Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-fHbp monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect. Immun. 79: 751-759.
10. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764 -769.
11. Guc D, et al. 1993. Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium. Rheumatol Int. 13:139 -146.
12. Harris SL, Finn A, Granoff DM. 2003. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidisdiphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect. Immun. 71:3402-3408.
13. Harris SL, King WJ, Ferris W, Granoff DM. 2003. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect. Immun. 71: 275-286.
14. Johansson L, et al. 2003. CD46 in meningococcal disease. Science 301: 373-375.
15. Johansson L, et al. 2005. Human-like immune responses in CD46 transgenic mice. J. Immunol. 175:433-440.
16. Katz Y, Strunk RC. 1988. Synthesis and regulation of complement protein factor H in human skin fibroblasts. J. Immunol. 141:559 -563.
17. Kazatchkine MD, Fearon DT, Austen KF. 1979. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J. Immunol. 122:75-81.
18. + T lymphocyte function. Infect. Immun. 75: 4449-4455.
19. Lewis LA, et al. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6:e1001027.
20. Lewis LA, et al. 2008. Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect. Immun. 76:339 -350.
21. Madico G, et al. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510.
22. Moe GR, Zuno-Mitchell P, Lee SS, Lucas AH, Granoff DM. 2001. Functional activity of anti-neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect. Immun. 69:3762-3771.
23. Munoz-Canoves P, Tack BF, Vik DP. 1989. Analysis of complement factorHmRNA expression: dexamethasone and IFN-gamma increase the level of H in L cells. Biochemistry 28:9891-9897.
24. Ngampasutadol J, et al. 2008. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J. Immunol. 180:3426 -3435.
25. Ripoche J, et al. 1988. Interferon gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J. Exp. Med. 168:1917-1922.
26. Saukkonen K. 1988. Experimental meningococcal meningitis in the infant rat. Microb. Pathog. 4:203-211.
27. Schneider MC, et al. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566 -7575.
28. Schryvers AB, Morris LJ. 1988. Identification and characterization of the transferrin receptor from Neisseria meningitidis. Mol. Microbiol. 2:281-288.
29. Timmerman JJ, et al. 1996. Differential expression of complement components in human fetal and adult kidneys. Kidney Int. 49:730 -740.
30. Toropainen M, et al. 1999. The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine 17:2677-2689.
31. Toropainen M, et al. 2005. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines. Vaccine 23: 4821-4833.
32. Vogel U, Claus H, Heinze G, Frosch M. 1999. Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates. Infect. Immun. 67:954 -957.
33. Vogel U, Hammerschmidt S, Frosch M. 1996. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitidis serogroup B are prerequisites for virulence of meningococci in the infant rat. Med. Microbiol. Immunol. (Berl.) 185:81-87.
34. Welsch JA, Granoff D. 2007. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin. Vaccine Immunol. 14:1596 -1602.
35. Welsch JA, Granoff D. 2004. Naturally acquired passive protective activity against Neisseria meningitidis group C in the absence of serum bactericidal activity. Infect. Immun. 72:5903-5909.
36. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061.
37. Welsch JA, Rossi R, Comanducci M, Granoff DM. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172:5606-5615.
38. Zarantonelli ML, et al. 2007. Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect. Immun. 75:5609-5614.